# Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

> **NCT05984342** · PHASE1 · RECRUITING · sponsor: **Affiliated Cancer Hospital of Shantou University Medical College** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05984342
- **Lead sponsor:** Affiliated Cancer Hospital of Shantou University Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-02
- **Primary completion:** 2025-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984342, "Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05984342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*